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Epidemiology of microscopic colitis
We read the interesting paper by Pardi et al on
the epidemiology of microscopic colitis in
Olmsted County, Minnesota, USA (Gut 2007;
56: 504–8). They concluded that the incidence
of microscopic colitis increased significantly
over time, and by the end of the study, the
incidence and prevalence were significantly
higher than reported previously. In fact,
compared with other epidemiological studies,
in the last years of the study period they
describe the highest incidence figures of
microscopic colitis ever reported.
However, is difficult to compare the crude
incidence rates of several studies if we do not
know the age structure of the population
pyramid of each geographical area. As micro-
scopic colitis is associated with older age, a
higher incidence will be expected among aging
populations. A solution for this is to report the
standardised incidence rates; however, they are
not reported in most of the published epide-
miological studies. Another possibility is to
describe the population pyramid of each
geographical area. We think that the paper of
Pardi et al would have been more under-
standable if they had described the population
pyramid of Olmsted County. In our epidemio-
logical study on the incidence of microscopic
colitis in Terrassa, Spain,1 we reported the
population pyramid. Thus, Pardi et al should
assess if there are any differences in the age
structure and sex structure of the population
pyramids between Olmsted County and
Terrassa. In this sense, if population pyramids
were similar, they could conclude that there is
a true difference in the incidence of micro-
scopic colitis.
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Authors’ response
As Ferna´ndez-Bann˜ares et al point out, it is
difficult to compare crude incidence or pre-
valence rates across populations with different
demographic structures. They suggest that we
report our population pyramid to aid in
interpreting the difference in microscopic
colitis incidence observed in Minnesota com-
pared with Spain. However, this would not be
appropriate as there is no simple way to
integrate the population structure with the
various age- and sex-specific incidence rates
and arrive at any kind of coherent conclusion.
Instead, as they suggest, one should standar-
dise the local incidence rates to an external
reference population, which we, in fact, did in
our paper.1 As we standardised our rates to the
2000 US white population, it would be the
demographic ‘‘pyramid’’ to consider.
Standardising their age- and sex-specific inci-
dence rates to this same reference population
to enable a direct comparison would be even
better. Unfortunately, the age- and sex-specific
incidence rates with which to accomplish this
comparison are not reported in their paper.
The remaining alternative is to carry out an
indirect standardisation, whereby we apply our
own age- and sex-specific incidence rates to
their population structure. Thus, if the age-
and sex-specific incidence rates for microscopic
colitis in Olmsted County, Minnesota, USA, in
1985–20011 are applied to the comparable age-
and sex-specific denominator populations in
the Hospital Mu´tua de Terrassa health district
of Terrassa, Spain in 1993–7, then one would
expect to see 73 cases of microscopic colitis
instead of the 60 cases that were actually
observed. Thus, the Olmsted County rates are
still higher even after accounting for any
demographic differences between the two
populations.
Therefore, explanations other than differ-
ences in the underlying age structure in our
respective populations must be considered.
One possible explanation, as discussed in our
paper, is different exposure rates in the two
populations to certain environmental factors,
such as medications, associated with micro-
scopic colitis.2 Higher incidence rates could also
be expected if a higher percentage of our
population underwent sigmoidoscopy or colo-
noscopy with mucosal biopsies for the evalua-
tion of diarrhoea—that is, differential
application of the diagnostic test.
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Non-endoscopic
immunocytological screening test
for Barrett’s oesophagus
Surveillance strategies or chemoprevention of
clinically diagnosed Barrett’s oesophagus are
unlikely to alter population mortality from
oesophageal adenocarcinoma since it is esti-
mated that only 5% patients with Barrett’s
oesophagus are diagnosed, despite the increas-
ing use of endoscopy.1 Endoscopic screening
for Barrett’s oesophagus in white men aged
over 50 years with chronic heartburn has
therefore been advocated in the US.2
However, the prohibitive cost of endoscopy
and the pathological expertise required make
this screening programme problematic.
The aim of this study was to develop a
screening test that did not rely on endoscopy
and would be applicable to primary care. A
non-endoscopic cytological test, which has
been successfully used for the diagnosis of
oesophageal squamous carcinomas in high-risk
areas, was adapted by combining it with
immunocytology. The device (bought from
Nanru Technologies, Bellville, South Africa)
consists of a sponge contained within a
gelatine capsule that dissolves in the stomach
within 5 min (fig 1A,B).3 Liquid-based cytology
was used to create a cell monolayer and the
slides created were stained for minichromo-
some maintenance protein 2 (Mcm2). Mcm2 is
a proliferation marker that is abnormally
expressed at the luminal surface in Barrett’s
oesophagus, with expression indices that cor-
relate with the degree of dysplasia.4
Following approval from the Cambridge
Local Research Committee, 43 patients with
known Barrett’s oesophagus (defined by endo-
scopy and a diagnosis of intestinal metaplasia)
and 54 healthy volunteers were recruited
(table 1). Diagnostic endoscopy was voluntary
for healthy subjects, and, unfortunately,
almost all (95%) refused. The participants
rated the acceptability of the capsule sponge
as 4.0 (2.0–9.0) using a linear scale of 0 (worst
imaginable experience) to 10 (very enjoyable
experience), where 5 was neither pleasant nor
unpleasant. Of the patients with Barrett’s
oesophagus, 80% stated that they would
choose the capsule sponge in preference to
endoscopic surveillance. There were no com-
plications, and 91 of 96 (94.8%) samples were
adequate for analysis. The squamous (red
arrow) and columnar cells (black arrow) were
easily distinguishable (fig 1C,D) and good-
quality immunostaining for Mcm2 was
obtained (fig 1D).
A total of 27 of 40 (67.5%) specimens of
Barrett’s oesophagus were positive compared
with 17 of 52 (32.6%) specimens from healthy
volunteers, giving a sensitivity and specificity
of 67.5% and 67.3%, respectively. However,
patients with Barrett’s oesophagus with a
positive test had a statistically longer segment
than those with a negative test (p = 0.01);
therefore, if only patients with Barrett’s oeso-
phagus with a segment longer than 3 cm are
considered as true Barrett’s oesophagus, the
sensitivity and specificity become 76.0% and
62.7%, respectively. Since most volunteers did
not undergo endoscopy, it was impossible to
ascertain if they had Barrett’s oesophagus.
Heartburn is the primary risk factor for the
presence of Barrett’s oesophagus, and since
nine (53%) Mcm2 positive controls were
patients with a history of heartburn vs three
(8%) for the Mcm2 negative patients, there is a
possibility that patients with heartburn might
have Barrett’s oesophagus. To correct for this
possible bias, a post hoc analysis excluding all
patients with heartburn was performed and
the percentage of controls with a positive test
result decreased from 37.5% to 20%. In this
subgroup analysis, the sensitivity and specifi-
city were 67.5% and 80% for all patients, and
54.3% and 86.7%, respectively, for patients
with Barrett’s oesophagus with a segment
longer than 3 cm.
In summary, the capsule sponge is accepta-
ble to patients and applicable to primary care,
thus bypassing the need for screening endo-
scopy. The immunostained monolayer speci-
men is amenable to automated microscopy
processing. However, further refinements in
technique to increase the sensitivity and
specificity of this test are necessary before
population-based studies can be performed,
especially since the quoted specificity applies to
a population with a 44% incidence of Barrett’s
oesophagus, and will be much lower if used in
the general population. Overall, this proof-of-
principle study suggests that a non-endoscopic
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